|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000147443 |
Summary for DOK2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000147443 | Gene symbol | DOK2 |
| Gene name | docking protein 2 | |
| HGNC | 2991 | |
| Entrez ID | 9046 | |
| Gene type | protein_coding | |
| Synonyms | DOK2|p56dok-2|Dok-2 | |
| UniProtAcc | O60496 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for DOK2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| DOK2 | 3.62e+02 | 1.13e+00 | 3.21e-01 | 3.51e+00 | 4.53e-04 | 1.38e-03 | THCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| DOK2 | 2.82e+02 | 1.10e+00 | 4.08e-01 | 2.71e+00 | 6.80e-03 | 2.37e-02 | KIRP |
Top |
Sex-biased somatic mutation for DOK2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for DOK2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LIHC | cg03732056 | chr8:21913548 | CGI:chr8:21912183-21912569 | promoter,gene body,CDS,UTR,exon | 4.00e-01 | 2.91e-01 | 4.00e+00 | 6.39e-05 | 5.00e-04 | 1.09e-01 |
| KICH | cg03732056 | chr8:21913548 | CGI:chr8:21912183-21912569 | promoter,gene body,CDS,UTR,exon | 4.77e-01 | 3.50e-01 | 2.06e+00 | 3.92e-02 | 4.64e-02 | 1.27e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BLCA | cg02837301 | chr8:21912184 | CGI:chr8:21912183-21912569 | promoter,gene body | 5.02e-01 | 6.17e-01 | -3.16e+00 | 1.59e-03 | 3.28e-03 | -1.15e-01 |
| LIHC | cg03732056 | chr8:21913548 | CGI:chr8:21912183-21912569 | promoter,gene body,CDS,UTR,exon | 2.91e-01 | 5.22e-01 | -5.71e+00 | 1.12e-08 | 8.70e-08 | -2.31e-01 |
| LIHC | cg09314421 | chr8:21913741 | CGI:chr8:21912183-21912569 | UTR,promoter,exon,gene body | 4.50e-01 | 5.93e-01 | -4.02e+00 | 5.88e-05 | 1.29e-04 | -1.43e-01 |
| LIHC | cg13292636 | chr8:21913747 | CGI:chr8:21912183-21912569 | UTR,promoter,exon,gene body | 4.93e-01 | 6.38e-01 | -3.99e+00 | 6.67e-05 | 1.45e-04 | -1.44e-01 |
| LIHC | cg21031128 | chr8:21913767 | CGI:chr8:21912183-21912569 | UTR,promoter,exon,gene body | 6.11e-01 | 7.39e-01 | -3.39e+00 | 6.92e-04 | 1.14e-03 | -1.28e-01 |
| LIHC | cg08288130 | chr8:21914029 | CGI:chr8:21912183-21912569 | promoter | 6.30e-01 | 7.35e-01 | -2.28e+00 | 2.25e-02 | 2.48e-02 | -1.05e-01 |
| ESCA | cg03732056 | chr8:21913548 | CGI:chr8:21912183-21912569 | promoter,gene body,CDS,UTR,exon | 3.85e-01 | 5.17e-01 | -2.16e+00 | 3.05e-02 | 4.39e-02 | -1.32e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg15316716 | chr8:21912286 | CGI:chr8:21912183-21912569 | promoter,exon,CDS,gene body | 6.92e-01 | 8.18e-01 | -8.91e+00 | 5.10e-19 | 2.54e-18 | -1.26e-01 |
| KIRC | cg15316716 | chr8:21912286 | CGI:chr8:21912183-21912569 | promoter,exon,CDS,gene body | 6.51e-01 | 7.54e-01 | -2.65e+00 | 8.15e-03 | 1.50e-02 | -1.03e-01 |
| LUAD | cg15316716 | chr8:21912286 | CGI:chr8:21912183-21912569 | promoter,exon,CDS,gene body | 6.39e-01 | 7.44e-01 | -2.99e+00 | 2.81e-03 | 6.43e-03 | -1.05e-01 |
| LUAD | cg08288130 | chr8:21914029 | CGI:chr8:21912183-21912569 | promoter | 5.75e-01 | 7.14e-01 | -2.45e+00 | 1.44e-02 | 2.04e-02 | -1.39e-01 |
| LUAD | cg16476235 | chr8:21914157 | CGI:chr8:21912183-21912569 | promoter | 7.29e-01 | 8.69e-01 | -2.18e+00 | 2.90e-02 | 3.37e-02 | -1.40e-01 |
Top |
Exon skipping events with PSI in TCGA for DOK2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for DOK2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for DOK2 |
| TFs related to DOK2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| READ | PLAGL2 | DOK2 | 4.30e+00 | 9.87e-01 | 3.08e+00 | 2.05e-03 | Male-biased |
| DOK2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for DOK2 |
| RBPs related to ES in DOK2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| DOK2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs78693232 | chr8:13985068:A:G | - | 0.13856403674403 | 0.0351843943235668 | KIRP | Female-baised eQTL |
| rs73212385 | chr8:13987670:C:T | - | 0.228706657698036 | 0.0465499719548626 | KIRP | Female-baised eQTL |
| rs75225172 | chr8:13999815:G:A | - | 0.228706657698036 | 0.0465499719548626 | KIRP | Female-baised eQTL |
| rs10888102 | chr8:15067985:C:A | - | -0.199502992016765 | 0.000335864560405232 | BLCA | Female-baised eQTL |
| rs75357232 | chr8:20583937:A:G | - | 0.20020894606321 | 0.00221882353142075 | BLCA | Female-baised eQTL |
| rs75694429 | chr8:20589004:G:A | - | 0.184137680322719 | 0.00458126533989688 | BLCA | Female-baised eQTL |
| rs1871659 | chr8:20592498:G:A | - | 0.174835750931054 | 0.00966484964519917 | BLCA | Female-baised eQTL |
| rs76394190 | chr8:20569056:C:T | - | 0.173367553897886 | 0.00976692943440517 | BLCA | Female-baised eQTL |
| rs289511 | chr8:13383749:A:T | - | -0.138511912807288 | 0.0112171063100198 | BLCA | Female-baised eQTL |
| rs2722895 | chr8:28314879:C:T | - | -0.13387139003479 | 0.0128504761036542 | BLCA | Female-baised eQTL |
| rs2722896 | chr8:28315105:A:G | - | -0.13387139003479 | 0.0128504761036542 | BLCA | Female-baised eQTL |
| rs62502292 | chr8:16050012:A:G | - | 0.267319528428818 | 0.0129615604751407 | BLCA | Female-baised eQTL |
| rs2614083 | chr8:28313363:G:T | - | -0.133521583600863 | 0.0129685846976706 | BLCA | Female-baised eQTL |
| rs2614084 | chr8:28313413:A:G | - | -0.133521583600863 | 0.0129685846976706 | BLCA | Female-baised eQTL |
| rs2722894 | chr8:28314022:A:T | - | -0.133521583600863 | 0.0129685846976706 | BLCA | Female-baised eQTL |
| rs2614085 | chr8:28314060:G:A | - | -0.133521583600863 | 0.0129685846976706 | BLCA | Female-baised eQTL |
| rs62492373 | chr8:16064468:T:C | - | 0.266472860037439 | 0.01379696156588 | BLCA | Female-baised eQTL |
| rs75280450 | chr8:16066563:A:G | - | 0.266472860037439 | 0.01379696156588 | BLCA | Female-baised eQTL |
| rs12543496 | chr8:29112406:C:G | - | 0.154097008038352 | 0.0151612631239406 | BLCA | Female-baised eQTL |
| rs17215039 | chr8:13374204:T:A | - | 0.194726391614005 | 0.021241158106529 | BLCA | Female-baised eQTL |
| rs17215195 | chr8:13376067:A:G | - | 0.194726391614005 | 0.021241158106529 | BLCA | Female-baised eQTL |
| rs73205736 | chr8:13376609:A:G | - | 0.194726391614005 | 0.021241158106529 | BLCA | Female-baised eQTL |
| rs12550612 | chr8:23109256:G:A | - | -0.125506793338097 | 0.022600990007525 | BLCA | Female-baised eQTL |
| rs167042 | chr8:13384552:C:T | - | -0.203999176358924 | 0.0226595051804783 | BLCA | Female-baised eQTL |
| rs73665366 | chr8:15011065:C:T | - | 0.160360884382431 | 0.0331303486501955 | BLCA | Female-baised eQTL |
| rs11203675 | chr8:15011606:C:A | - | -0.160360884382431 | 0.0331303486501955 | BLCA | Female-baised eQTL |
| rs6992611 | chr8:15011977:G:A | - | 0.160360884382431 | 0.0331303486501955 | BLCA | Female-baised eQTL |
| rs9918919 | chr8:23109777:G:C | - | -0.121380392706633 | 0.0364076557934767 | BLCA | Female-baised eQTL |
| rs7002838 | chr8:27900874:C:G | - | 0.212216012881775 | 0.0367180918355633 | BLCA | Female-baised eQTL |
| rs10111172 | chr8:23111578:T:C | - | -0.120178428973848 | 0.0394544928059824 | BLCA | Female-baised eQTL |
| rs1484768 | chr8:16045452:G:C | - | 0.226773175243614 | 0.0396132334871248 | BLCA | Female-baised eQTL |
| rs11574276 | chr8:31101484:T:A | - | 0.144140945026495 | 0.0418374762843546 | BLCA | Female-baised eQTL |
| rs73228694 | chr8:31104902:G:A | - | 0.144140945026495 | 0.0418374762843546 | BLCA | Female-baised eQTL |
| rs17650903 | chr8:31104903:C:A | - | 0.144140945026495 | 0.0418374762843546 | BLCA | Female-baised eQTL |
| rs62506090 | chr8:31106090:A:T | - | 0.144140945026495 | 0.0418374762843546 | BLCA | Female-baised eQTL |
| rs17651080 | chr8:31110157:A:C | - | 0.144140945026495 | 0.0418374762843546 | BLCA | Female-baised eQTL |
| rs62502290 | chr8:16048142:C:A | - | 0.22578754779696 | 0.0422869636491653 | BLCA | Female-baised eQTL |
| rs62502316 | chr8:16050032:G:A | - | 0.22578754779696 | 0.0422869636491653 | BLCA | Female-baised eQTL |
| rs62492405 | chr8:16094286:A:C | - | 0.236814563642778 | 0.0443302424023668 | BLCA | Female-baised eQTL |
| rs62492406 | chr8:16095054:A:T | - | 0.236814563642778 | 0.0443302424023668 | BLCA | Female-baised eQTL |
| rs118111862 | chr8:13395479:T:C | - | 0.244543734895123 | 0.0451849124930191 | BLCA | Female-baised eQTL |
| rs11988785 | chr8:16093369:C:T | - | 0.236266738809355 | 0.0459863421678606 | BLCA | Female-baised eQTL |
| rs79382796 | chr8:16086662:T:C | - | 0.235885037755484 | 0.0468371546162508 | BLCA | Female-baised eQTL |
| rs112681058 | chr8:16090564:T:C | - | 0.235016027264397 | 0.0493831188498045 | BLCA | Female-baised eQTL |
| rs2722911 | chr8:28311334:C:T | - | -0.115055372782631 | 0.0494246162422011 | BLCA | Female-baised eQTL |
| rs2614080 | chr8:28311606:G:A | - | -0.115055372782631 | 0.0494246162422011 | BLCA | Female-baised eQTL |
| rs2722908 | chr8:28311713:A:G | - | -0.115055372782631 | 0.0494246162422011 | BLCA | Female-baised eQTL |
| rs1026353 | chr8:15092024:A:G | - | -0.0614981750868765 | 0.0116351081350842 | LUAD | Female-baised eQTL |
| rs5006988 | chr8:16422975:A:G | - | 0.0735281558636933 | 0.0339730680912056 | LUAD | Female-baised eQTL |
| rs62504215 | chr8:15571336:C:G | - | 0.0765558374450487 | 0.0360160418025484 | LUAD | Female-baised eQTL |
| rs76060711 | chr8:16334865:T:G | - | 0.082226961573585 | 0.0425672632521789 | LUAD | Female-baised eQTL |
| rs79514829 | chr8:16319247:C:A | - | 0.0849532905576346 | 0.0433518893750885 | LUAD | Female-baised eQTL |
| rs62504194 | chr8:15562005:T:G | - | 0.0479039829795852 | 0.0468653896547257 | LUAD | Female-baised eQTL |
| rs62504195 | chr8:15562349:C:T | - | 0.0479039829795852 | 0.0468653896547257 | LUAD | Female-baised eQTL |
| rs1366957 | chr8:16317662:T:C | - | 0.0808690184301414 | 0.0499715475486879 | LUAD | Female-baised eQTL |
| rs78454631 | chr8:15258110:C:T | - | 0.0724398464069524 | 0.0295691025863392 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs7812583 | chr8:20483857:C:T | - | 0.0451180208908047 | 0.0462113131139773 | LIHC | Male-baised eQTL |
| rs80207740 | chr8:21922426:C:G | - | 0.100221080441614 | 0.02129454267749 | KIRC | Male-baised eQTL |
| rs58141407 | chr8:21934261:C:T | - | 0.0935938830066641 | 0.0267388365198416 | KIRC | Male-baised eQTL |
| rs17581959 | chr8:21950246:A:G | - | 0.0923322144270337 | 0.0332236219440769 | KIRC | Male-baised eQTL |
| rs76008177 | chr8:21944761:C:T | - | 0.0886550088501162 | 0.0454284623533059 | KIRC | Male-baised eQTL |
| rs12679696 | chr8:17383207:C:T | - | 0.0492908059570365 | 0.00930937909924533 | COAD | Male-baised eQTL |
| rs725949 | chr8:17387002:T:C | - | 0.0453327065057734 | 0.0220179618124862 | COAD | Male-baised eQTL |
| rs9325882 | chr8:21406467:G:A | - | 0.0458515893795243 | 0.0248964383725657 | COAD | Male-baised eQTL |
| rs2321847 | chr8:26242212:G:C | - | 0.0906919941257919 | 0.0295458612669505 | COAD | Male-baised eQTL |
| rs6994023 | chr8:21422813:G:A | - | 0.0490523602987261 | 0.0296744696645706 | COAD | Male-baised eQTL |
| rs10089703 | chr8:21418887:G:T | - | 0.0467227411726004 | 0.0296917968344175 | COAD | Male-baised eQTL |
| rs2912243 | chr8:21388289:C:A | - | -0.0449002761436312 | 0.0299458125558936 | COAD | Male-baised eQTL |
| rs13269262 | chr8:21419849:C:T | - | 0.0480125054953969 | 0.0315553480348249 | COAD | Male-baised eQTL |
| rs10503641 | chr8:18973778:G:A | - | 0.0524200038254669 | 0.0343910556105553 | COAD | Male-baised eQTL |
| rs7831273 | chr8:21424258:C:T | - | 0.0473750367642104 | 0.0360583037950061 | COAD | Male-baised eQTL |
| rs2410686 | chr8:21393504:A:C | - | -0.044135957077748 | 0.0368018206449606 | COAD | Male-baised eQTL |
| rs2912241 | chr8:21385874:G:A | - | -0.0532193233001947 | 0.037299028184161 | COAD | Male-baised eQTL |
| rs9644576 | chr8:21406819:G:C | - | 0.0434749749035231 | 0.0373092705784324 | COAD | Male-baised eQTL |
| rs13263769 | chr8:21416265:G:A | - | 0.0465842733642608 | 0.0379955903081874 | COAD | Male-baised eQTL |
| rs1002833 | chr8:21417424:A:T | - | 0.0465842733642608 | 0.0379955903081874 | COAD | Male-baised eQTL |
| rs13273582 | chr8:21415960:T:C | - | 0.0465128727393286 | 0.0393303514820017 | COAD | Male-baised eQTL |
| rs1834531 | chr8:21391610:G:A | - | -0.0432855101377002 | 0.0425671093927848 | COAD | Male-baised eQTL |
| rs752619 | chr8:21393833:A:G | - | -0.043156547616927 | 0.0438971466703075 | COAD | Male-baised eQTL |
| rs17245234 | chr8:26230610:A:G | - | 0.0854837581029329 | 0.0454967715491729 | COAD | Male-baised eQTL |
| rs55638656 | chr8:21393505:T:A | - | -0.0427828103805194 | 0.0458276535436742 | COAD | Male-baised eQTL |
| rs4501588 | chr8:27112174:A:T | - | 0.0427122231168105 | 0.0493245411163984 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000147443 |
| CpG Site: cg00255726 | |
| Position to Gene: gene | |
| Male Effect: -0.319967297311051 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg00255726 | chr8:21911603 | gene | -0.319967297311051 | 1.8860071399336e-05 | -0.35133693846488634 | 7.049379709423995e-08 | LUAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of DOK2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000147443 | DOK2 | C0024121 | Lung Neoplasms | 1 | CTD_human |
| ENSG00000147443 | DOK2 | C0242379 | Malignant neoplasm of lung | 1 | CTD_human |
